Rapid Therapeutic Science Laboratories, Inc. — Cyborg Score 2/10
Challenged
Cannabinoid pharmaceutical delivery systems
Strategic Profile
In September 2023, the SEC filed a civil action alleging that RTSL and its CEO engaged in fraudulent unregistered securities offerings that raised at least $3.25 million from more than 50 investors in 15 states. The SEC's complaint alleged the company made false statements about certification from a non-existent industry board (CMDICB) and falsely claimed major sales contracts and laboratory certifications, with the alleged certification being invented by a Schmidt business associate. The company remains micro-cap with minimal market viability.
Cyborg Score Rationale
RTSL faces fundamental credibility issues following an SEC enforcement action (September 2023) alleging fraudulent securities offerings and material misrepresentations. The company's market capitalization is negligible at $114K as of 2026, and its manufacturing operations have been paused. Regulatory path for CBD products remains highly uncertain.
Top Insights
September 2023: SEC filed civil fraud action against RTSL and CEO for unregistered securities offerings ($3.25M+ raised) and material misrepresentations regarding certifications, contracts, and facility compliance
Manufacturing operations paused; company pursuing investigational new drug (IND) application with FDA for CBD metered-dose inhaler, but FDA approval pathway for CBD remains uncertain and limited
Market capitalization collapsed to $114K as of June 2026; OTC Pink Sheets listing with minimal liquidity and shareholder confidence
Company attempted Nasdaq up-listing via reverse stock split (March 2022) but failed to achieve capital markets access; regulatory and reputational barriers remain insurmountable
Named Competitors
Metered-dose inhalers (CBD/pharmaceutical) — Established pharmaceutical inhaler technology and manufacturing
Generic/branded inhalers — Global respiratory pharmaceutical delivery systems
CBD wellness products — CBD consumer health and wellness brand
Recent Developments
(September 2023) SEC civil enforcement action filed against RTSL and CEO for fraudulent unregistered securities offerings and false statements regarding certifications and contracts
(December 2022) Three proprietary pharmaceutical-grade patents moved from provisional to non-provisional status
(March 2023) Company announced strategic alignment following FDA cannabis research guidance clarification
Open the full interactive Rapid Therapeutic Science Laboratories, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.